{"id":4674,"date":"2020-11-30T18:38:26","date_gmt":"2020-11-30T23:38:26","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/"},"modified":"2024-12-03T14:57:21","modified_gmt":"2024-12-03T19:57:21","slug":"nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/","title":{"rendered":"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study"},"content":{"rendered":"<h2>Abstract<\/h2>\n<p><strong>Background:<\/strong> The discovery that nerve growth factor (NGF) metabolism is altered in Down syndrome (DS) and Alzheimer\u2019s disease (AD) brains offered a framework for the\u00a0 identification of novel biomarkers signalling NGF deregulation in AD pathology.<\/p>\n<p><strong>Methods:<\/strong> We examined levels of NGF pathway proteins (proNGF, neuroserpin, tissue plasminogen activator [tPA], and metalloproteases [MMP]) in matched cerebrospinal fluid (CSF)\/plasma samples from AD-symptomatic (DSAD) and AD-asymptomatic (aDS) individuals with DS, as well as controls (HC).<\/p>\n<p><strong>Results:<\/strong> ProNGF and MMP-3 were elevated while tPA was decreased in plasma from individualswithDS.CSFfromindividualswithDSshowedelevatedproNGF,neuroserpin, MMP-3, and MMP-9. ProNGF and MMP-9 in CSF differentiated DSAD from aDS (area under the curve = 0.86, 0.87). NGF pathway markers associated with CSF amyloid beta and tau and differed by sex.<\/p>\n<p><strong>Discussion: <\/strong>Brain NGF metabolism changes can be monitored in plasma and CSF, supporting relevance in AD pathology. These markers could assist staging, subtyping, or precision medicine for AD in DS.<\/p>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-4674","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract Background: The discovery that nerve growth factor (NGF) metabolism ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T19:57:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/\",\"name\":\"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2020-11-30T23:38:26+00:00\",\"dateModified\":\"2024-12-03T19:57:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study - CCNA - CCNV","og_description":"Abstract Background: The discovery that nerve growth factor (NGF) metabolism ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T19:57:21+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/","name":"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2020-11-30T23:38:26+00:00","dateModified":"2024-12-03T19:57:21+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/nerve-growth-factor-ngf-pathway-biomarkers-in-down-syndrome-prior-to-and-after-the-onset-of-clinical-alzheimers-disease-a-paired-csf-and-plasma-study-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: A paired CSF and plasma study"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/4674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=4674"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=4674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}